ICU Medical (NASDAQ:ICUI) surprises with Q3 2026 sales
ICU Medical reported Q3 2026 revenue of $560.4M, beating estimates by 1.5%, with adjusted EPS of $2.44, a 13.6% beat. Adjusted EBITDA was $113.9M, a 7% beat. Management reiterated full-year adjusted EPS guidance of $8.80 and EBITDA guidance of $425M. Operating and free cash flow margins improved significantly year-over-year.
How this was made
The 30-second read
Why it matters
The earnings beat reinforces the company's growth narrative and may attract short-term buying.
Market read
Earnings surprise provides a clear trading catalyst for ICUI.
What to watch
Potential supply chain constraints could affect future quarters.
Background
ICU Medical (NASDAQ:ICUI) released its Q3 2026 earnings, showing beats on revenue and EPS.
Ticker impact
ICU Medical reported Q3 2026 results that beat revenue and EPS estimates and reiterated full-year EPS guidance.
likely upward pressure as the market prices in the earnings beat and steady guidance
Revenue and EPS both exceeded consensus, and guidance remains unchanged, supporting a bullish short-term move.
Market effects
Positive earnings may lift other medical device peers.
U.S. healthcare sector could see modest gains.
Limited to U.S. listed medical device space.
Counterpoint
Some investors may question the sustainability of margin expansion.
Key entities
- CompanyICU Medical
Medical device manufacturer reporting earnings.
